A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. [electronic resource]
Producer: 20100923Description: 32-7 p. digitalISSN:- 1095-6859
- Adult
- Aged
- Aged, 80 and over
- CA-125 Antigen -- blood
- Disease-Free Survival
- Fallopian Tube Neoplasms -- drug therapy
- Female
- Humans
- Indazoles
- Middle Aged
- Neoplasm Recurrence, Local -- blood
- Ovarian Neoplasms -- blood
- Peritoneal Neoplasms -- drug therapy
- Pyrimidines -- adverse effects
- Sulfonamides -- adverse effects
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.